Eli Lilly's oral weight loss drug impresses in Phase III

Orforglipron, a new daily tablet for the treatment of type 2 diabetes and weight loss, has shown results on par with injectable drugs like Ozempic – sending the stock soaring.

Create account to read this article for free

Get free access to a limited number of articles.

Eli Lilly's oral weight loss drug impresses in Phase III

Create account to read this article for free

Merck gears up in lung diseases with giant acquisition

AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million

AlzeCure Pharma: “We have good momentum”

Notes

iZafe takes the next step in the Nordics – begins Finnish partnership for Dosell

Senzime's partner receives FDA approval for TetraGraph module

Ellen sells the business for SEK 13,3 million

Oncopeptides increases sales in the second quarter

Alvotech acquires Ivers-Lee Group in Switzerland

NEWSLETTER

NEWS

Merck gears up in lung diseases with giant acquisition

AstraZeneca strengthens gene therapy portfolio with deals worth up to $825 million

AlzeCure Pharma: “We have good momentum”

Upcoming events!

Investing in Life Science

Life Science Summit

You deserve the best!

Chronicles

The EU's new life science strategy – a step in the right direction or just fluff?

Early signs of spring in an otherwise frosty biotech landscape

Trump is once again waving tariff threats – are they just empty words?

Recommended

The pharmaceutical industry's call to the EU: Act!

Lift for Active Biotech after positive study results

Donald Trump's killing blow against the pharmaceutical industry

BiBB writes LOI for launch in the USA

New generation of cancer drugs challenges Keytruda

Tip the editors